Study of adebrelimab combinations for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a drug called adebrelimab, used alone or with other treatments, for people with advanced solid tumors, including extensive-stage small cell lung cancer. It aims to see if adding this drug helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumors, including extensive-stage small cell lung cancer or other types confirmed by biopsy.
- You are between 18 and 80 years old.
- You are willing to use effective birth control during and for 90 days after the study if you could become pregnant.
- You do not have certain cancers like brain tumors or melanoma.
- You do not have active infections like HIV or tuberculosis, or autoimmune diseases that need strong medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This study looks at how well adebrelimab works and how safe it is in real-world settings for people with advanced small cell lung cancer that has spread. It may help doctors understand if this treatment is a good option for patients like you.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This study is testing a drug called adebrelimab for people with advanced small cell lung cancer. It collects real-world information on how well the treatment works and how it affects patients.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This trial tests a combination of two immunotherapy drugs (adebrelimab and SHR-8068) plus chemotherapy for people with advanced or spreading non-small cell lung cancer that has certain genetic changes (STK11, KEAP1, or KRAS mutations). It aims to see if this combination can shrink tumors and help people live longer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.